SCHEMBL7572207

SCHEMBL7572207

NC(=O)c1ncn([C@@H]2O[C@H](CO)C[C@H]2O)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ADORA1 P30542 2/20 0.62
ALDH1A1 P00352 2/20 0.62
TSHR P16473 2/20 0.62
GLA P06280 1/20 0.62
EIF4E P06730 1/20 0.62
CYP3A4 P08684 1/20 0.62
TOP1 P11387 1/20 0.62
THPO P40225 1/20 0.62
PMP22 Q01453 1/20 0.62
TMEM97 Q5BJF2 2/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
PNP P00491 3/20 0.46
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13186245 1.00 LMNA (0.62) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL13186258 1.00 LMNA (0.62) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL13754496 1.00 LMNA (0.62) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL21888891 0.83 LMNA (0.51) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL23316241 0.81 LMNA (0.52) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL21887941 0.80 LMNA (0.46) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL21888132 0.79 LMNA (0.45) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL21888080 0.77 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL11654052 0.77 LMNA (0.62) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL13754497 0.77 LMNA (0.62) LMNASMN1; SMN2ADORA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023014360-A1 TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS OCTAGON THERAPEUTICS, INC. (US) 2023-02-09 WO disclosed
EP-1240899-A2 Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections ICN Pharmaceuticals, Inc. (US) 2002-09-18 EP disclosed
EP-1174141-A2 Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes ICN Pharmaceuticals, Inc. (US) 2002-01-23 EP disclosed
EP-0879056-A4 MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN-m(3) AND RIBAVIRIN-m(3) ANALOGS IN ACTIVATED T-LYMPHOCYTES ICN PHARMACEUTICALS (US) 1999-01-13 EP disclosed
EP-0879056-A1 MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN$m(3) AND RIBAVIRIN$m(3) ANALOGS IN ACTIVATED T-LYMPHOCYTES ICN Pharmaceuticals, Inc. (US) 1998-11-25 EP disclosed
WO-1997026883-A1 MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN® AND RIBAVIRIN® ANALOGS IN ACTIVATED T-LYMPHOCYTES ICN PHARMACEUTICALS, INC. (US) 1997-07-31 WO disclosed